Project Number 3P01AG003949-37S1 Agency/Funding Organization NIA Funding Year 2020 View Full Project Details for Predictive Metabolite Signature for Alzheimer's Disease - a Nested Case-Control Study Research Categorization Primary Disease / Condition Alzheimer's Disease Vascular Dementia/Dysfunction CADRO Category D. Population Studies 1. U.S.-Based Cohorts Einstein Aging Study (EAS) (U.S., Multimodal Risk Factors; 70+) Researcher and Organization Principal Investigator LIPTON, RICHARD B Principal Investigator First Name RICHARD Principal Investigator Last Name LIPTON Awardee Organization ALBERT EINSTEIN COLLEGE OF MEDICINE Awardee State New York, N.Y. Contact PI Country United States Project Detail Funding Opportunity Announcement PAR-18-030: NIA Revision and Resubmission Program Project Applications (P01 Clinical Trial Optional) FY Overall Cost $421,857 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official ANDERSON, DALLAS Related Resources Repository [NIAGADS] Mayo GWAS [AlzPED] Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. [AlzPED] Intracranial Adeno-Associated Virus-Mediated Delivery of Anti-Pan Amyloid β, Amyloid β40, and Amyloid β42 Single-Chain Variable Fragments Attenuates Plaque Pathology in Amyloid Precursor Protein Mice